Abbott Initiates Clinical Trial to Study Drug Eluting Bioresorbable Therapy for Treatment of Peripheral Artery Disease

Abbott

today announced the initiation of ESPRIT I, a first-of-its-kind clinical trial in Europe evaluating the safety and performance of the novel Esprit™ drug eluting bioresorbable vascular scaffold for the treatment of blockages in the superficial femoral arteries and iliac arteries that have resulted in claudication (leg pain upon walking). Claudication is the most common symptom in patients with peripheral artery disease, and is associated with diminished physical activity and poor quality of life for patients. The SFA and iliac arteries, located in the upper leg and pelvis, are common areas of blockage in patients with PAD. The first patient was treated with an Esprit BVS as part of the trial by Marc Bosiers, M.D., head of the Department of Vascular Surgery at St. Blasius Hospital in Dendermonde, Belgium. The Esprit drug eluting BVS is designed specifically for use in peripheral arteries and is made of polylactide, the same proven biocompatible material used in the company's Absorb™ drug eluting BVS for coronary artery disease. Absorb is authorized for sale in Europe and is investigational in the United States. Esprit is designed to restore blood flow by opening a blocked vessel and providing support until it is healed. Once the vessel can remain open without the extra support, the scaffold is designed to dissolve, leaving the vessel free of a permanent metallic implant. Because a permanent implant is not left behind, clinical outcomes may be improved and options for retreatment of the vessel preserved.